Radicle Science – Healthcare Data News

May 5, 2022May 9, 2022 Competitor News

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization...

February 11, 2022February 15, 2022 Clinical Trials Competitor News

Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC

Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in...

December 8, 2021 Competitor News RWE Study

Radicle Science Releases Initial Findings from Largest Real World Evidence Study Evaluating Effectiveness of CBD Products

December 07, 2021 07:00 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Radicle Science, a transformative healthtech B-corp validating natural products for the first time, announces initial findings from the Radicle ACES...